Topical XXXX Use in Knee Periprosthetic Joint Infection is Safe and Effective.

@entity1 @entity2045 @entity19 @entity928 @entity1151 @entity281 @entity927 @entity1793 @entity715
UNASSIGNED: Introduction   @entity927 ( @entity928 ) has been shown to decrease hemoglobin loss and reduce the need for transfusions in primary hip and knee arthroplasty. Our study evaluated the safety and efficacy of topical @entity928 in revision TKA for @entity281 ( @entity281 ). Methods   We performed a retrospective review of @entity1 who underwent removal of hardware with antibiotic spacer placement (stage 1) and/or revision TKA (stage 2) for @entity281 at our institution between September 2007 and July 2013. During that time, 49 @entity1 underwent stage-1 procedures (20 knees with @entity928 , 29 without @entity928 ) and 47 @entity1 underwent stage-2 revisions (28 with @entity928 , 19 without @entity928 ). We evaluated hemoglobin loss, need for transfusion, reinfection rate, length of stay (LOS), complications, and mortality with and without the use of @entity928 in these @entity1 . All data sets were analyzed with a two-sample t-test. Results   Average follow-up was 3.15 years (range, 1-7 years). @entity928 use led to a significantly lower percentage drop in the postoperative lowest hemoglobin compared with the preoperative hemoglobin in stage-1 surgeries (19.8 vs. 30.05%, p   =   0.0004) and stage-2 revisions (24.5 vs 32.01%, p   =   0.01). In both groups, @entity928 use was associated with a significant reduction in transfusion rates (stage-1, 25 vs 51.7%, p   =   0.04; stage-2, 25 vs. 52.6%, p   =   0.05). There was a nonstatistical decreased LOS in both groups in which @entity928 was used (stage 1, 5.15 vs. 6.72 days, p   =   0.055; stage 2, 5.21 vs. 6.84 days, p   =   0.09). There was no difference in the reinfection rate (4 vs. 4, p   =   0.56) or mortality rate between groups (0 vs. 2 non- @entity928 group). A single @entity2045 deep vein @entity715 occurred in a stage-1 @entity1 who received @entity928 , and no @entity1151 occurred. Conclusion   We show that topical @entity928 is safe and effective for use in both stages of revision TKA for @entity281 . Previous studies have shown @entity928 to aggravate a @entity1793 in @entity19 ; however, topical @entity928 doesn't appear to negatively effect on the treatment of @entity281 in our @entity1 and did not increase the reinfection, complication, or mortality rate.
